Some other factors driving the microfluidic devices market are rise in the commercial and analytical application of these devices and use of microfluidic products for miniaturization of chip.

Moreover some of the challenges faced by the market are adherence to stringent regulatory requirements to decelerate growth and geometrical and surface chemistry issues.

The use of microfluidic devices has been gaining importance into recent classification of research areas that target integration of laboratory protocols into miniaturized devices known as lab on chip.

This process includes many steps such as mixing, pre-treatment, reaction, separation, and pre-concentration. These processes help to reduce the cost and consume less reagent/sample, which is further helpful in various medical diagnosis with the help of blood drop. The miniaturization technique is expected to drive the microfluidic devices market, as this technique helps to reduce the overall cost of screening the compounds for cell biology problems by the pharmaceutical companies. Also the miniaturization technique helps in the reduction of analysis time and carry parallel assay in microfluidic devices, which is further expected to support the growth of this market.

Competitive Analysis:

Hoffmann-la Roche AG, Abbott laboratories, Siemens healthcare GMBH, Agilent technologies, Inc., Fluidigm corporation, bio-rad laboratories, ink, Cepheid, Raindance technologies, Inc., Dolomite centre, Micronit microfluidics, Johnson & Johnson, Becton, Dickinson and Company, These are some of the prominent players at the forefront of competition in the Global Microfluidic Devices Market.

Global Microfluidics Device Regional Analysis:

North America is the largest market for microfluidic devices, with factors such as growing old age population, increasing healthcare awareness, rising chronic and lifestyle diseases, technological developments for various home use applications and wider insurance infrastructure facilities driving the growth of microfluidic devices. With the rise in overall healthcare expenditure, the use of these devices has increased, since these devices provide accurate, reliable and quick results for early detection and prevention of diseases.

Due to its early introduction and wider applications in industries, use of microfluidic devices is high in North America as compared to other geographies. According to the European Federation of Pharmaceutical Industries and Associations, in 2014, the North American pharmaceutical market accounted for about 41.0% share of the global pharmaceutical market. High research and development expenditures in new drug lead to increase in the demand for various microfluidic devices for toxicity testing in the drug development process.

The European market for microfluidic devices is driven by increasing diagnostic requirements, due to rise in lifestyle associated diseases and increasing geriatric population. On the other hand, the increasing healthcare expenditure in the region has led to a shift in the focus of healthcare from hospitals to home, leading to increased use of microfluidic devices in the region.

According to the European Federation of Pharmaceutical Industries and Associations, R&D investment in Europe was about $40.2 billion, which lead to increased production of drugs in pipeline. The use of microfluidic devices is also expected to increase microreactors in drug synthesis and toxicity testing in drug development.

There are various regulatory issues related to microfluidic devices used for pharmaceutical research, point of care testing and clinical and veterinary diagnosis. The European Medical Devices Directives regulates the laws on performance and safety of the medical devices

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/microfluidics-device-market-684